Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Asthma/COPD (EU5) 2018

Product Code:
Publication Date:
June 2018

Market barriers affect only 12 percent of asthma/COPD prescriptions in Europe. Is your brand losing out?

Market barriers affect just over 12 percent of all prescriptions for asthma/COPD treatments in Europe, and certain brands are losing out on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access Impact: Asthma/COPD (EU5) [2018].

Based on a survey of 150 pulmonologists and primary care physicians from the EU5 markets (France, Germany, Italy, Spain and the UK), the report covers 11 major therapies from GSK, Chiesi, Teva, AstraZeneca, Novartis and Boehringer Ingelheim. Handy graphs and charts reveal which  of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Not yout market? Click here to see the US report.

Request sample pages

Top Takeaways

  • Barriers affect just over 1 in 10 prescriptions. Some brands are making hay, while others are losing market share. Is your brand a leader or laggard? And is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • One brand sees the biggest share increase. Is its lead too big to overcome? What can other brands do to catch up?
  • Three brands see a significant loss. Could market share losses be due to low prescribing rates, or is some other market dynamic at play? And perhaps most importantly, can this be prevented?
  • Eliminating barriers would close gaps at the bottom of the table. Only gaps at the bottom of the table would be closed in a barrier free world. Will your brand experience an increase in market share in a barrier free world?
  • Perception could be the problem. For some brands, up to 35 percent of physicians are unaware of them. Could improving awareness and understanding amongst these physicians improve market shares?

Insight into 11 Major Asthma/COPD Drugs


  • Seretide (fluticasone/salmeterol; GSK)
  • Relvar Ellipta (vilanterol/fluticasone furoate; GSK)
  • Seebri (glycopyrronium; Novartis)
  • Spiriva (tiotropium; Boehringer Ingelheim)
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Ultibro (indacaterol/glycopyrronium; Novartis)
  • Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi)


  • Xolair (omalizumab; Novartis)
  • Cinqaero (reslizumab; Teva)
  • Nucala (mepolizumab; GSK)
  • Fasenra (benralizumab; AstraZeneca)

Exploring Important Market Access Issues

Market Access Impact: Asthma/COPD (EU5) explores key issues affecting asthma/COPD drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 pulmonologists and primary care physicians—30 from each EU5 country (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world. All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with asthma/COPD in total in the last month

We conducted the survey between June 4-7, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved